ALRN — Aileron Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $84.86m
- $158.96m
Annual cashflow statement for Aileron Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -29.4 | -21.2 | -26.2 | -27.3 | -15.7 |
| Depreciation | |||||
| Non-Cash Items | 1.89 | 1.8 | 2.05 | 1.88 | 1.19 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.85 | -1.28 | 0.242 | 0.42 | -5.38 |
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Cash from Operating Activities | -26.5 | -20.5 | -23.8 | -24.9 | -19.8 |
| Capital Expenditures | -0.151 | -0.005 | -0.157 | 0 | — |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -2.66 | 6.42 | -35.8 | 26.5 | 16.2 |
| Acquisition of Business | |||||
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -2.81 | 6.41 | -35.9 | 26.5 | 16.2 |
| Financing Cash Flow Items | 0 | — | — | — | 15.8 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 24 | 15.8 | 55.7 | 0 | 15.8 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -5.32 | 1.74 | -4.01 | 1.59 | 12.1 |